Targeting HLA‐E in Lung Cancer: The Therapeutic Potential of IRF5‐Engineered M1‐Macrophage‐Derived Exosomes
Xuqin Feng, Xiangyu Lai, Mingming Zhou, Jun Bie, Tingting Li, Dan Wang, Silin Chen, Xin Hu, Chunyu Wang, Peng Xu · 2024
Read Targeting HLA‐E in Lung Cancer: The Therapeutic Potential of IRF5‐Engineered M1‐Macrophage‐Derived Exosomes by Xuqin Feng, Xiangyu Lai, Mingming Zhou, Jun Bie, Tingting Li, Dan Wang, Silin Chen, Xin Hu, Chunyu Wang, Peng Xu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11611755.txt.
Description
Xuqin Feng and nine co-authors test a new way to attack lung cancer using tiny packets shed by immune cells. Their 2024 study builds packets, called exosomes, from M1 macrophages, a cell type that fights tumors. The packets carry a factor named IRF5, which marks these fighter cells.
In lab dishes, the engineered packets slowed the growth, movement, and spread of lung cancer cells. In mice, they also shrank tumors. The team traced the effect to a protein called HLA-E, whose level the factor raises in cancer cells. Lowering the factor had the opposite effect, and restoring HLA-E canceled it. The work points to a possible new treatment path.
Catalog record
| CREATOR | Xuqin Feng, Xiangyu Lai, Mingming Zhou, Jun Bie, Tingting Li, Dan Wang, Silin Chen, Xin Hu, Chunyu Wang, Peng Xu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |